ELEVATE-TN Study. New data of acalabrutinib in first-line treatment of chronic lymphocytic leukemia. Resolution

封面
  • 作者: Poddubnaya I.1, Al-Radi L.2,3, Byalik T.4, Kaplanov K.5, Molostvova V.6, Nikitin E.7,8, Pospelova T.9, Ptushkin V.10,8, Samoilova O.11, Stadnik E.12, Tumyan G.13
  • 隶属关系:
    1. Federal State Budgetary Educational Institution of Higher Professional Education “Russian Medical Academy of Continuing Professional Education” of the Ministry of Health of Russia
    2. Federal State Budgetary Institution National Medical Research Center for Hematology
    3. Ministry of Health of Russia
    4. Federal State Budgetary Institution National Medical Research Center for Oncology named after N.N. Blokhina Ministry of Health of Russia
    5. Volgograd Regional Clinical Oncology Center
    6. KGBUZ Regional Clinical Hospital No. 1 named after prof. S.I. Sergeeva Ministry of Health of the Khabarovsk Territory
    7. GBUZ “City Clinical Hospital named after S.P. Botkin ”, Moscow Department of Health
    8. Moscow City Hematology Center
    9. FSBEI HE "Novosibirsk State Medical University" of the Ministry of Health of Russia
    10. City Clinical Hospital named after S.P. Botkin, Moscow Department of Health
    11. GBUZ NO Nizhny Novgorod Regional Clinical Hospital named after N. A. Semashko
    12. FSBEI HE First St. Petersburg State Medical University named after Acad. I.P. Pavlova Ministry of Health of Russia
    13. Federal State Budgetary Institution National Medical Research Center for Oncology named after N.N. Blokhina Ministry of Health of Russia
  • 期: 卷 22, 编号 1 (2020)
  • 页面: 31-33
  • 栏目: CLINICAL ONCOLOGY
  • URL: https://journals.rcsi.science/1815-1434/article/view/34167
  • DOI: https://doi.org/10.26442/18151434.2020.1.200090
  • ID: 34167

如何引用文章

全文:

详细

Over the past decade, we have seen a significant change in modern approaches in the first-line treatment of chronic lymphocytic leukemia (CLL). The CLL-10 study data established the FCR regimen as the treatment of choice for younger patients with limited comorbidities, while for patients older than 65 years, the BR regimen is more often considered as less toxic one. According to published data, 46% of patients with newly diagnosed CLL have comorbidities. Moreover, high-risk patients with del(17p) and/or TP53 mutation do not have response on immunochemotherapy (ICT) most often. Thus, about 1/2 of the patients cannot be treated or will not respond to standard ICT regimens. Targeted therapy with Bruton’s tyrosine kinase (BTK) inhibitors is an important option of the first-line treatment of patients with CLL. Acalabrutinib is a highly selective second-generation BTK inhibitor that does not inhibit EGFR, ITK or TEC targets. Acalabrutinib in combination with obinutuzumab or as monotherapy can be considered as a highly effective and safe option of the first line of CLL therapy. Based on the hight selectivity of the agent, acalabrutinib can be considered as the preferable option for patients who are not eligible for ICT, including patients with commodities, such as cardiovascular diseases or risk factors for their development.

作者简介

Irina Poddubnaya

Federal State Budgetary Educational Institution of Higher Professional Education “Russian Medical Academy of Continuing Professional Education” of the Ministry of Health of Russia

编辑信件的主要联系方式.
Email: or@hpmp.ru

academician of the Russian Academy of Sciences, doctor of medical sciences, professor

俄罗斯联邦, Moscow

Lyubov Al-Radi

Federal State Budgetary Institution National Medical Research Center for Hematology; Ministry of Health of Russia

Email: or@hpmp.ru

candidate of medical sciences

俄罗斯联邦, Moscow

Tatyana Byalik

Federal State Budgetary Institution National Medical Research Center for Oncology named after N.N. Blokhina Ministry of Health of Russia

Email: or@hpmp.ru

candidate of medical sciences

俄罗斯联邦, Moscow

Kamil Kaplanov

Volgograd Regional Clinical Oncology Center

Email: or@hpmp.ru

Candidate of Medical Sciences

俄罗斯联邦, Volgograd

Valentina Molostvova

KGBUZ Regional Clinical Hospital No. 1 named after prof. S.I. Sergeeva Ministry of Health of the Khabarovsk Territory

Email: or@hpmp.ru

Candidate of Medical Sciences

俄罗斯联邦, Khabarovsk

Evgeniy Nikitin

GBUZ “City Clinical Hospital named after S.P. Botkin ”, Moscow Department of Health; Moscow City Hematology Center

Email: or@hpmp.ru

Doctor of Medical Sciences, Professor

俄罗斯联邦, Moscow

Tatyana Pospelova

FSBEI HE "Novosibirsk State Medical University" of the Ministry of Health of Russia

Email: or@hpmp.ru

Doctor of Medical Sciences, Professor

俄罗斯联邦, Novosibirsk

Vadim Ptushkin

City Clinical Hospital named after S.P. Botkin, Moscow Department of Health; Moscow City Hematology Center

Email: or@hpmp.ru

Doctor of Medical Sciences, Professor

俄罗斯联邦, Moscow

Olga Samoilova

GBUZ NO Nizhny Novgorod Regional Clinical Hospital named after N. A. Semashko

Email: or@hpmp.ru

Candidate of Medical Sciences

俄罗斯联邦, Nizhny Novgorod

Elena Stadnik

FSBEI HE First St. Petersburg State Medical University named after Acad. I.P. Pavlova Ministry of Health of Russia

Email: or@hpmp.ru

Candidate of Medical Sciences

俄罗斯联邦, St. Petersburg

Gayane Tumyan

Federal State Budgetary Institution National Medical Research Center for Oncology named after N.N. Blokhina Ministry of Health of Russia

Email: or@hpmp.ru

Doctor of Medical Sciences

俄罗斯联邦, Moscow

参考

  1. Thompson PA, Tam CS, O’Brien SM et al. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood 2016; 127: 303.
  2. Nitin Jain et al. Approaches to Chronic Lymphocytic c Leukemia Therapy in the Era of New Agents: The Conundrum of Many Options. N Jain 2018 ASCO Educational book; p. 580–91.
  3. Woyach JA. Acalabrutinib with obinutuzumab in treatment-naïve and relapse/refractory chronic leukemia: 3-year follow-up. EHA 2019 Abstract PF377
  4. Eichhorst B et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol 2016; 17: 928–42.
  5. Gribben JG. How I treat CLL up front. Blood 2010; 115 (2): 187–97.
  6. Weide R et al. Survival improvement of patients with chronic lymphocytic leukemia (CLL) in routine care 1995–2017. Blood 2018; 132 (Suppl. 1): 4823.
  7. Sanam Shafaattalab et al. Ibrutinib Displays Atrial-Specific Toxicity in Human Stem Cell-Derived Cardiomyocytes. Stem Cell Reports 2019; 12; 996–1006.
  8. Wu et al. Acalabrutinib (ACP-196): a selective second generation BTK inhibitor. J Hematol Oncol 2016; 9: 21.
  9. McMullen JR et al. Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. Blood 2014; 124: 3829–30.
  10. Mato et al. Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial. Am J Hematol 2018; 93: 1394–401.
  11. Byrd JC et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med 2016; 374 (4): 323–32.
  12. Covey T et al. Abstract 2596: ACP-196: a novel covalent Bruton’s tyrosine kinase (Btk) inhibitor with improved selectivity and in vivo target coverage in chronic lymphocytic leukemia (CLL) patients. Cancer Res 2015; 75 (15 Suppl.): 2596.
  13. Sharman JP et al. ELEVATE TN: Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naive Chronic Lymphocytic Leukemia (CLL). Abstract 31 at: American Society of Hematology 2019 Annual Meeting and Exposition.
  14. https://clinicaltrials.gov/ct2/show/NCT02475681?term=acalabrutinib&draw=6&rank=47

版权所有 © Consilium Medicum, 2020

Creative Commons License
此作品已接受知识共享署名-非商业性使用 4.0国际许可协议的许可。
 


##common.cookie##